Papers
Topics
Authors
Recent
Gemini 2.5 Flash
Gemini 2.5 Flash
169 tokens/sec
GPT-4o
7 tokens/sec
Gemini 2.5 Pro Pro
45 tokens/sec
o3 Pro
4 tokens/sec
GPT-4.1 Pro
38 tokens/sec
DeepSeek R1 via Azure Pro
28 tokens/sec
2000 character limit reached

Pharmacokinetic Measurements in Dose Finding Model Guided by Escalation with Overdose Control (2404.11406v1)

Published 17 Apr 2024 in stat.AP and stat.CO

Abstract: Oncology drug development starts with a dose escalation phase to find the maximal tolerable dose (MTD). Dose limiting toxicity (DLT) is the primary endpoint for dose escalation phase. Traditionally, model-based dose escalation trial designs recommend a dose for escalation based on an assumed dose-DLT relationship. Pharmacokinetic (PK) data are often available but are currently only used by clinical teams in a subjective manner to aid decision making. Formal incorporation of PK data in dose-escalation models can make the decision process more efficient and lead to an increase in precision. In this talk we present a Bayesian joint modeling framework for incorporating PK data in Oncology dose escalation trials. This framework explores the dose-PK and PK-DLT relationships jointly for better model informed dose escalation decisions. Utility of the proposed model is demonstrated through a real-life case study along with simulation.

Definition Search Book Streamline Icon: https://streamlinehq.com
References (32)
  1. Cancer phase I clinical trials: efficient dose escalation with overdose control. Statistics in Medicine, 17(10):1103–1120.
  2. Cheung, Y. K. (2005). Coherence principles in dose-finding studies. Biometrika, 92(4):863–873.
  3. Pharmacologically guided phase I clinical trials based upon preclinical drug development. JNCI: Journal of the National Cancer Institute, 82(16):1321–1326.
  4. Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep, 70(1):73–80.
  5. Corporation, C. S. (1992). EaSt: A software package for the design and interim monitoring of group sequential clinical trials.
  6. A practical design for a dual-agent dose-escalation trial that incorporates pharmacokinetic data. Statistics in Medicine, 34(13):2138–2164.
  7. Handbook of Statistics in Clinical Oncology. CRC Press.
  8. Dose-Finding Designs for Early-Phase Cancer Clinical Trials: A Brief Guidebook to Theory and Practice. Springer.
  9. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer, 136(5):E359–E386.
  10. Geller, N. L. (1984). Design of phase I and II clinical trials in cancer: a statistician’s view. Cancer Investigation, 2(6):483–491.
  11. Holford, N. H. (1995). The target concentration approach to clinical drug development. Clinical Pharmacokinetics, 29(5):287–291.
  12. Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion. Pharmaceutical Statistics: The Journal of Applied Statistics in the Pharmaceutical Industry, 8(1):38–49.
  13. A modified toxicity probability interval method for dose-finding trials. Clinical Trials, 7(6):653–663.
  14. Critical aspects of the Bayesian approach to phase I cancer trials. Statistics in Medicine, 27(13):2420–2439.
  15. A Bayesian industry approach to phase I combination trials in oncology. In Zhao, W. and Yang, H., editors, Statistical Methods in Drug Combination Studies, pages 95–135. Chapman & Hall/CRC Press: Boca Raton, FL.
  16. Newell, D. R. (1994). Pharmacologically based phase I trials in cancer chemotherapy. Hematology/Oncology Clinics of North America, 8(2):257–275.
  17. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics, pages 33–48.
  18. Continual reassessment method: a likelihood approach. Biometrics, pages 673–684.
  19. Improved designs for dose escalation studies using pharmacokinetic measurements. Statistics in Medicine, 15(15):1605–1618.
  20. Plummer, M. (2003). JAGS: A program for analysis of Bayesian graphical models using Gibbs sampling. In Proceedings of the 3rd International Workshop on Distributed Statistical Computing, volume 124, pages 1–10. Vienna, Austria.
  21. Plummer, M. (2019). rjags: Bayesian Graphical Models using MCMC. R package version 4-10.
  22. R Core Team (2019). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria.
  23. Competing designs for phase I clinical trials: a review. Statistics in Medicine, 21(18):2757–2770.
  24. Ceritinib in ALK-rearranged non–small-cell lung cancer. New England Journal of Medicine, 370:1189–1197.
  25. Bayesian dose-finding phase I trial design incorporating pharmacokinetic assessment in the field of oncology. Pharmaceutical Statistics, 17(6):725–733.
  26. Dose finding with escalation with overdose control (EWOC) in cancer clinical trials. Statistical Science, pages 217–226.
  27. dfpk: an R-package for Bayesian dose-finding designs using pharmacokinetics (PK) for phase I clinical trials. Computer Methods and Programs in Biomedicine, 157:163–177.
  28. Dose-finding methods for phase I clinical trials using pharmacokinetics in small populations. Biometrical Journal, 59(4):804–825.
  29. Easy-to-implement Bayesian methods for dose-escalation studies in healthy volunteers. Biostatistics, 2(1):47–61.
  30. A Bayesian approach for dose-escalation in a phase I clinical trial incorporating pharmacodynamic endpoints. Journal of Biopharmaceutical Statistics, 17(6):1117–1129.
  31. Optimal Bayesian-feasible dose escalation for cancer phase I trials. Statistics and Probability Letters, 38(3):215–220.
  32. Comparative eview of novel model-assisted designs for phase I clinical trials. Statistics in Medicine, 37(14):2208–2222.

Summary

We haven't generated a summary for this paper yet.

Ai Sparkles Streamline Icon: https://streamlinehq.com Summarize Now
X Twitter Logo Streamline Icon: https://streamlinehq.com

Tweets